Premium
The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab‐containing line of therapy
Author(s) -
Szabo Agoston Gyula,
Thorsen Jonathan,
Iversen Katrine Fladeland,
Levring Mette Bøegh,
Preiss Birgitte,
Helleberg Carsten,
Breinholt Marie Fredslund,
Hermansen Emil,
Gjerdrum Lise Mette Rahbek,
Bønløkke Søren Thorgaard,
Nielsen Katrine,
Kjeldsen Eigil,
Teodorescu Elena Manuela,
Dokhi Marveh,
Kurt Eva,
Strandholdt Casper Nørgaard,
Andersen Mette Klarskov,
Vangsted Annette Juul
Publication year - 2022
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.26449
Subject(s) - daratumumab , multiple myeloma , medicine , life expectancy , oncology , bortezomib , environmental health , population